ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 313

Magnetic Resonance Imaging Outcomes Using an Intra-Articular Injection (SM04690) in the Treatment of Osteoarthritis of the Knee: Interim, Exploratory Analysis of Results from a Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study

Yusuf Yazici1, Sharmila Majumdar2, Timothy E. McAlindon3, Roy Fleischmann4, Allan Gibofsky5, Marc C. Hochberg6, Christopher J. Swearingen1, Anita DiFrancesco1, Jeyanesh R. S. Tambiah1, John Hood1 and Nancy E. Lane7, 1Samumed, San Diego, CA, 2Radiology, UCSF School of Medicine, San Francisco, CA, 3Rheumatology, Tufts Medical Center, Boston, MA, 4University of Texas Southwestern Medical Center, Dallas, TX, 5Weill Cornell Medical College and Hospital for Special Surgery, New York, NY, 6Department of Medicine, University of Maryland, Baltimore, MD, 7Center for Musculoskeletal Health, Univ of California at Davis, Sacramento, CA

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: cartilage, Magnetic resonance imaging (MRI), osteoarthritis and regeneration, WNT Signaling

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Sunday, November 8, 2015

Session Title: Osteoarthritis - Clinical Aspects Poster I: Treatments and Metabolic Risk Factors

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Knee
osteoarthritis (OA) is characterized by the destruction of articular cartilage,
subchrondral bone alterations and varying degrees of synovitis. Current OA
treatments are limited to relieving pain as there are no drug therapies
approved which treat the underlying cause of the disease. The Wnt signaling
pathway is known to play a central role in the formation of joint tissues and
altered Wnt signaling has been associated with cartilage loss in preclinical
and clinical studies.1 SM04690 is a small molecule inhibitor of the
Wnt pathway which is administered via intra-articular (IA) injection. This
report provides interim magnetic resonance imaging (MRI) data from an ongoing
phase I randomized, double-blind, placebo-controlled, dose-escalation clinical
trial of SM04690 in knee OA subjects.

Methods: Subjects with symptomatic,
radiographic knee OA were randomized to receive a single IA injection in the
target knee with either 0.03, 0.07, 0.23 mg SM04690 or placebo (volume 2mLs) in
a 4:1 SM04690 (N=16):placebo (N=4) ratio. Knee MRIs
were obtained with a 16 channel knee coil on a 3.0T MRI machine using a standard
diagnostic protocol, and were collected at baseline visit (which could occur ≤28
days prior to study injection), Week 12 and 24. Average cartilage thickness
over covered subchondral bone was reported for medial
and lateral femoral condyles as well as medial and lateral tibial
plateaus. Also, the average of the lowest 1% of cartilage thickness was
reported for all 4 compartments. The total for both average thickness and
lowest thickness were derived by summing each of the 4 compartments’
observations. An exploratory analysis of change in imaging outcomes was
conducted using repeated measures analysis of covariance (ANCOVA) adjusting for
baseline.

Results: 61 subjects (average age 62.6
[±5.7] years, female N=41 [67%], average BMI 30.4 [±4.7] kg/m2) were
enrolled. At time of abstract submission, 41 subjects had completed the 24-week trial: Cohort 1: 0.03 mg (N=17), Cohort 2: 0.07 mg
(N=16) and placebo (N=8). Cohort 2 24-week imaging data are under review and
Cohort 3 (subjects treated with 0.23 mg [N=16] and placebo [N=4]) is ongoing;
these data are not reported at this time. At Week 12, total average cartilage
thickness decreased 0.07 mm and 0.02 mm for 0.03 mg and 0.07 mg, respectively,
adjusting for the baseline value (Table). However, total average thickness of
the lowest 1% increased 0.10 mm and 0.08 mm for 0.03 mg and 0.07 mg,
respectively, adjusting for baseline value. Moreover, total average cartilage
thickness increased 0.02 mm and total average thickness of the lowest 1%
increased 0.12 mm in the 0.03 mg group at Week 24.

Conclusion: Preliminary data
from this interim, exploratory analysis of MRI outcomes from an ongoing Phase 1
trial suggest that SM04690 may maintain or increase cartilage thickness, both
at the site of maximal cartilage degradation as well as overall.

Reference: 1. Gelse
K. Osteoarthr Cartil
2012; 20(2):162-71

 

                

Description: \samdcsvr01SAMPROGRAMS2. OsteoarthritisClinicalPhase IProtocol - SM04690-01PublicationsACR2015chg_imaging.png


Disclosure: Y. Yazici, Samumed, 3; S. Majumdar, GE Healthcare, 2,Samumed, 5; T. E. McAlindon, Sanofi Aventis, Samumed, Flexion, Novartis, Federal Trade Commission, Abbvie, McNeil Consumer HC, 5,Tufts MCPO, 3; R. Fleischmann, Abbvie, 2,Amgen, 2,Ardea, 2,AstraZeneca, 2,Bristol-Myers Squibb, 2,Celgene, 2,GlaxoSmithKline, 2,Janssen Pharmaceutica Product, L.P., 2,Eli Lilly and Company, 2,Merck Pharmaceuticals, 2,Pfizer Inc, 2,Resolve, 2,Roche Pharmaceuticals, 2,Sanofi-Aventis Pharmaceutical, 2,UCB, 2,AbbVie, 5,Akros, 5,Amgen, 5,AstraZeneca, 5,Bristol-Myers Squibb, 5,Celgene, 5,Janssen Pharmaceutica Product, L.P., 5,Eli Lilly and Company, 5,Pfizer Inc, 5,Roche Pharmaceuticals, 5,UCB, 5; A. Gibofsky, Abbvie, Drais, Celgene, Horizon, Iroko, Medac, Pfizer Inc, Relburn, Samumed, and Takeda, 5,AbbVie, Amgen, Celgene, Iroko, Pfizer Inc, 8,AbbVie, Amgen, Bristol-Myers Squibb, GlaxoSmithKlyne, Johnson & Johnson, and Pfizer Inc, 1; M. C. Hochberg, Samumed, 5; C. J. Swearingen, Samumed, 3; A. DiFrancesco, Samumed, 3; J. R. S. Tambiah, Samumed, 3; J. Hood, Samumed, 3; N. E. Lane, Samumed, 5.

To cite this abstract in AMA style:

Yazici Y, Majumdar S, McAlindon TE, Fleischmann R, Gibofsky A, Hochberg MC, Swearingen CJ, DiFrancesco A, Tambiah JRS, Hood J, Lane NE. Magnetic Resonance Imaging Outcomes Using an Intra-Articular Injection (SM04690) in the Treatment of Osteoarthritis of the Knee: Interim, Exploratory Analysis of Results from a Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/magnetic-resonance-imaging-outcomes-using-an-intra-articular-injection-sm04690-in-the-treatment-of-osteoarthritis-of-the-knee-interim-exploratory-analysis-of-results-from-a-randomized-double-blin/. Accessed January 20, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/magnetic-resonance-imaging-outcomes-using-an-intra-articular-injection-sm04690-in-the-treatment-of-osteoarthritis-of-the-knee-interim-exploratory-analysis-of-results-from-a-randomized-double-blin/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.